Dihexa Acetate: Structure, Salt Form and Naming

Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.

Dihexa is listed in peptide catalogues and is not really handled like a peptide. The name is the clue: two hexanoyl groups attached to a very short angiotensin IV-derived core, and those two acyl chains dominate everything practical about the compound — its solubility, its stock preparation, and the way its identity has to be confirmed.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

What the structure is made of

Element	Role
Angiotensin IV-derived core	The pharmacophore; a short peptide sequence
Two hexanoyl groups	Added lipophilicity and metabolic stability
Basic site	Why the compound is supplied as a salt
Acetate counterion	Contributes mass that is not the active molecule

The 2015 review by Wright and colleagues in Progress in Neurobiology covers the development of angiotensin IV analogues and is the right reference for the design lineage. Reading it makes the logic clear: a short native fragment was too unstable and too polar to be useful, so the programme added lipophilic modifications. Dihexa is a product of that effort.

A terminological note worth making: because the molecule is a short peptide carrying substantial non-peptide modifications, descriptions of it as “a peptide” and “a small molecule” are both defensible. In the laboratory the second description is the more useful one, because it predicts the behaviour correctly.

The acetate question

Acetate is the counterion. Dihexa has a basic site, so after purification it is isolated as a salt rather than as a free base, and acetate is a common form after ion exchange from the trifluoroacetate that reverse-phase purification leaves behind.

Two consequences follow:

The acetate is part of the delivered mass. A quantity weighed out as the acetate salt contains less active molecule than the same weight of free base.
The molecular weight used in calculations must match the form supplied. Free base and acetate salt differ, and carrying a figure across from one to the other produces a systematic error in one direction.

The 2008 study by Roux and colleagues in the Journal of Peptide Science is the standard reference on removing and exchanging trifluoroacetate from cationic peptides, and it is worth knowing for a reason beyond bookkeeping: if a lot has not been exchanged, residual trifluoroacetate is present, and trifluoroacetate is not biologically inert in cell culture at sufficient levels. A certificate that does not name the counterion leaves this unresolved.

Why the mass check matters here more than usual

This compound circulates under several names and with varying stated salt forms. The 2020 study by Vanhee and colleagues in Drug Testing and Analysis is directly relevant: it examined putative cognitive-enhancing research peptides found in seized pharmaceutical preparations, and it exists because material in this category is not always what its label says.

The practical checks are short:

Is the exact structure stated, including both modifications and the salt form? A name alone does not identify the compound.
Is an observed mass given as a number? Compute the expected value for the stated form yourself and compare. A “conforms” statement is not this check.
Is the counterion named? Required for the molecular weight and relevant for cell work.
Is there a chromatogram? For a lipophilic compound, retention behaviour is informative and a single clean peak is meaningful evidence.

The general framework is in how to read a certificate of analysis, and the counterion arithmetic specifically in peptide counterions: TFA versus acetate.

Solubility is the first bench problem

Two hexanoyl chains make the molecule lipophilic. That was the design intention, and it means aqueous solubility is poor.

Step	Practice
Stock preparation	Organic co-solvent at a concentration confirmed to dissolve fully
Dilution	Into aqueous medium last, with mixing, co-solvent fraction as low as the assay allows
Vehicle control	Matched co-solvent concentration — not optional
Inspection	Check the diluted solution for haze against a dark background
Storage of stock	Aliquoted, sealed tightly, frozen; record the solvent

Precipitation on dilution is the characteristic silent failure. It can be partial, leaving an unknown concentration; it can be slow, developing over an incubation; and it affects the highest concentrations in a series preferentially, which flattens the top of a response curve in a way that mimics target saturation. Inspecting the wells is the cheapest way to tell those apart.

Reading the biology literature carefully

The published work on this compound requires more care than most, because its most-cited mechanistic paper was retracted in 2025 and a second from the same laboratory carries an expression of concern. That history is set out in what Dihexa is, and it is the reason the references here are limited to independent, unflagged work: the 2021 study by Sun and colleagues in APP/PS1 mice, and the 2018 systematic review by Ho and colleagues covering angiotensin IV-related cognitive studies.

Our Dihexa research material is supplied for laboratory research use. Certificates are available for listed products — contact us for the latest report. Where a comparison set includes conventional peptides, their concentration maths runs through net peptide content, which our reconstitution calculator handles; for this compound the inputs are the formula weight of the supplied salt and the solubility limit in the chosen solvent.

Open questions

What is the measured aqueous solubility limit under common culture conditions?
How much do stated salt forms vary between sources of this compound?
Does residual trifluoroacetate appear in lots described as acetate?

Frequently asked questions

What does the name Dihexa refer to?

The two hexanoyl groups attached to a short angiotensin IV-derived peptide core. The modifications are added to increase lipophilicity and metabolic stability relative to the parent fragment, and they dominate the molecule’s physical behaviour.

What does acetate mean on the label?

Acetate is the counterion supplied with the compound. Basic sites in the molecule are isolated as a salt after purification, and acetate is a common form after ion exchange. The acetate contributes mass that is not the active molecule.

Is Dihexa a peptide?

It is a heavily modified short peptide rather than a conventional one. The peptide core is only a few residues, and the acyl modifications change solubility and handling enough that it behaves more like a lipophilic small molecule in practice.

Why does the molecular weight need checking carefully?

Because the compound exists in the literature and in catalogues under several names and with different stated salt forms. The mass of the free base and of the acetate salt differ, and using the wrong figure introduces a systematic concentration error.

Is Dihexa water-soluble?

Poorly, by design. The two hexanoyl chains make it lipophilic, which was the point of adding them. An organic co-solvent is generally needed to prepare a stock, and precipitation on dilution into aqueous medium is the main practical failure.

References

Sun X, et al. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Sci. 2021. PMID: 34827486 https://pubmed.ncbi.nlm.nih.gov/34827486/
Ho JK, et al. Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies. Neurosci Biobehav Rev. 2018. PMID: 29733881 https://pubmed.ncbi.nlm.nih.gov/29733881/
Wright JW, et al. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Prog Neurobiol. 2015. PMID: 25455861 https://pubmed.ncbi.nlm.nih.gov/25455861/
Vanhee C, et al. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind. Drug Test Anal. 2020. PMID: 31667971 https://pubmed.ncbi.nlm.nih.gov/31667971/
Roux S, et al. Elimination and exchange of trifluoroacetate counter-ion from cationic peptides: a critical evaluation of different approaches. J Pept Sci. 2008. PMID: 18035848 https://pubmed.ncbi.nlm.nih.gov/18035848/